{"hands_on_practices": [{"introduction": "Successful enucleation requires careful preoperative planning to restore orbital volume, and correct implant sizing is critical for cosmesis and motility. This exercise provides practice in applying fundamental geometric principles to a core surgical planning task. By calculating the required implant diameter, you will translate a volumetric goal into a concrete surgical parameter, honing a foundational skill in ophthalmic plastic surgery. [@problem_id:4673946]", "problem": "An oculoplastic surgeon is planning a primary orbital implant following enucleation in an adult patient. To maintain realistic orbital volume and allow room for the ocular prosthesis and soft tissues, the surgeon elects to replace a fraction of the native globe volume with a single, solid, spherical implant. Assume the native adult globe volume is $7.4$ mL and that the chosen replacement fraction is $0.75$. Model the implant as a perfect sphere and assume continuum mechanics so that volume additivity is valid. Use fundamental geometric relations and unit conversions only. Take the unit equivalences $1$ mL $=$ $1$ cm$^{3}$ and $1$ cm $=$ $10$ mm. Compute the implant diameter that most closely matches the target replacement volume. Round your final answer to three significant figures. Express the diameter in millimeters (mm).", "solution": "The problem requires the calculation of the diameter of a spherical orbital implant based on a specified fraction of the native globe volume. The solution proceeds by first determining the target volume of the implant and then using the geometric formula for the volume of a sphere to find its corresponding diameter.\n\nFirst, we identify the given parameters:\nThe native adult globe volume is $V_{\\text{globe}} = 7.4$ mL.\nThe chosen replacement fraction is $f = 0.75$.\nThe unit equivalences are $1$ mL $= 1$ cm$^{3}$ and $1$ cm $= 10$ mm.\n\nThe target volume of the implant, $V_{\\text{implant}}$, is the specified fraction $f$ of the native globe volume $V_{\\text{globe}}$.\n$$V_{\\text{implant}} = f \\times V_{\\text{globe}}$$\nSubstituting the given values:\n$$V_{\\text{implant}} = 0.75 \\times 7.4 \\text{ mL} = 5.55 \\text{ mL}$$\n\nUsing the provided unit equivalence, we convert the implant volume from milliliters (mL) to cubic centimeters (cm$^3$):\n$$V_{\\text{implant}} = 5.55 \\text{ cm}^3$$\n\nThe implant is modeled as a perfect sphere. The volume $V$ of a sphere is related to its radius $r$ by the formula $V = \\frac{4}{3}\\pi r^3$. Since the diameter $d$ is twice the radius ($d = 2r$, or $r = \\frac{d}{2}$), we can express the volume in terms of the diameter:\n$$V = \\frac{4}{3}\\pi \\left(\\frac{d}{2}\\right)^3 = \\frac{4}{3}\\pi \\left(\\frac{d^3}{8}\\right) = \\frac{1}{6}\\pi d^3$$\n\nWe set this volume formula equal to the target implant volume, $V_{\\text{implant}}$, to solve for the diameter $d$:\n$$V_{\\text{implant}} = \\frac{1}{6}\\pi d^3$$\nRearranging the equation to solve for $d$:\n$$d^3 = \\frac{6 V_{\\text{implant}}}{\\pi}$$\n$$d = \\left(\\frac{6 V_{\\text{implant}}}{\\pi}\\right)^{1/3}$$\n\nNow, we substitute the numerical value of $V_{\\text{implant}}$ in cm$^3$:\n$$d = \\left(\\frac{6 \\times 5.55 \\text{ cm}^3}{\\pi}\\right)^{1/3} = \\left(\\frac{33.3}{\\pi}\\right)^{1/3} \\text{ cm}$$\n\nTo compute the numerical value of the diameter in centimeters:\n$$d \\approx \\left(\\frac{33.3}{3.14159...}\\right)^{1/3} \\text{ cm} \\approx (10.6000...)^{1/3} \\text{ cm} \\approx 2.19643 \\text{ cm}$$\n\nThe problem requires the diameter to be expressed in millimeters (mm). Using the conversion factor $1$ cm $= 10$ mm:\n$$d_{\\text{mm}} = d_{\\text{cm}} \\times 10 \\frac{\\text{mm}}{\\text{cm}}$$\n$$d_{\\text{mm}} \\approx 2.19643 \\times 10 \\text{ mm} \\approx 21.9643 \\text{ mm}$$\n\nFinally, we round the result to three significant figures as requested. The first three significant figures are $2$, $1$, and $9$. The fourth digit is $6$, which is greater than or equal to $5$, so we round up the third digit. Rounding $21.9$ up results in $22.0$.\n$$d_{\\text{mm}} \\approx 22.0 \\text{ mm}$$\nThe zero in the first decimal place is significant and must be included to indicate the precision of three significant figures.", "answer": "$$\n\\boxed{22.0}\n$$", "id": "4673946"}, {"introduction": "Following eye removal, recognizing and understanding complications like implant exposure and extrusion is paramount. These two adverse outcomes have distinct causes and management strategies. This problem challenges you to apply principles of biomechanics, wound healing, and infection to analyze clinical scenarios, enhancing your ability to diagnose the pathophysiology of surgical failures. [@problem_id:4673948]", "problem": "A $58$-year-old patient undergoes enucleation for a blind painful eye with presumed end-stage neovascular glaucoma and receives a porous polyethylene orbital implant of diameter $22$ $\\mathrm{mm}$, wrapped in donor sclera, with extraocular muscle reinsertion to the scleral wrap and layered closure of Tenon capsule and conjunctiva. At $3$ weeks, a $4$ $\\mathrm{mm}$ anterior area of conjunctival breakdown reveals the underlying white implant surface; the implant is stable to retropulsion, there is no purulent discharge, and the eyelids cover the defect. A different $45$-year-old patient, who underwent evisceration with placement of a non-porous polymethylmethacrylate (PMMA) implant, develops an infected socket at $2$ weeks and, despite antibiotics, returns at $6$ weeks with the implant displaced outside the socket and lying within the palpebral fissure.\n\nUsing the following fundamental bases:\n- The definition of implant exposure versus extrusion in an anophthalmic socket, derived from standard surgical failure modes in soft-tissue coverage and device seating.\n- Basic wound-healing phases (inflammation, proliferation, remodeling) and the requirement for adequate perfusion and fibrovascular support of an implant-tissue interface.\n- The law of Laplace for thin-walled spherical or spheroidal shells, where anterior lamellar tension $T$ scales with intraorbital pressure $P$, radius $r$, and tissue thickness $t$ as $T = \\dfrac{P r}{2 t}$, noting that increased $r$ or decreased $t$ raises $T$ at closure lines.\n- Principles of infectious pathophysiology including biofilm formation, chronic inflammation, and tissue necrosis leading to loss of mechanical integrity.\n\nWhich of the following statements most accurately distinguish exposure from extrusion and enumerate biomechanical and infectious etiologies that predispose to each outcome? Select all that apply.\n\nA. Implant exposure is characterized by loss or thinning of conjunctiva and Tenon capsule with the implant remaining seated within the socket; extrusion denotes displacement of the implant out of the socket such that it is no longer contained by the capsular and soft-tissue envelope, often protruding externally.\n\nB. For a given intraorbital pressure $P$, increasing implant radius $r$ while maintaining thin anterior coverage thickness $t$ raises anterior lamellar tension $T$ at suture lines per $T = \\dfrac{P r}{2 t}$, biomechanically predisposing to anterior exposure in the early postoperative period.\n\nC. Infectious colonization with biofilm is more strongly associated with early exposure than with late extrusion, independent of coverage thickness, because biofilms reduce friction at the implant–tissue interface and thereby protect closure lines from shear.\n\nD. In evisceration with a thin scleral shell, placement of an oversized non-porous PMMA implant increases the risk of extrusion, particularly in the setting of infection, because the lack of fibrovascular ingrowth and inflammatory necrosis undermine device seating and capsular containment.\n\nE. Pegging of a hydroxyapatite implant (a porous calcium phosphate implant) reduces exposure risk by mechanically isolating the anterior lamellae from implant motion, thereby lowering shear forces at the conjunctival surface.\n\nF. Postoperative radiotherapy to the orbit generally improves tissue vascularity and wound-healing strength, thereby reducing the likelihood of exposure at anterior closure lines.", "solution": "The problem statement describes two clinical scenarios involving orbital implants following eye removal and asks for an evaluation of several statements distinguishing implant exposure from extrusion and their respective etiologies, based on provided definitions and fundamental principles of biomechanics, wound healing, and infection.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Case 1:**\n    *   Patient: $58$-year-old.\n    *   Procedure: Enucleation for blind, painful eye (presumed end-stage neovascular glaucoma).\n    *   Implant: Porous polyethylene, diameter $22$ $\\mathrm{mm}$, wrapped in donor sclera.\n    *   Technique: Extraocular muscles reinserted to scleral wrap; layered closure of Tenon capsule and conjunctiva.\n    *   Outcome at $3$ weeks: A $4$ $\\mathrm{mm}$ anterior conjunctival breakdown revealing the implant surface.\n    *   Signs: Implant is stable to retropulsion, no purulent discharge, eyelids cover the defect.\n\n*   **Case 2:**\n    *   Patient: $45$-year-old.\n    *   Procedure: Evisceration with a non-porous polymethylmethacrylate (PMMA) implant.\n    *   Outcome at $2$ weeks: Infected socket, treated with antibiotics.\n    *   Outcome at $6$ weeks: Implant displaced outside the socket, lying within the palpebral fissure.\n\n*   **Fundamental Bases:**\n    1.  Definition of implant exposure versus extrusion based on surgical failure modes (soft-tissue coverage vs. device seating).\n    2.  Wound healing principles: phases (inflammation, proliferation, remodeling) and the need for perfusion and fibrovascular support.\n    3.  Law of Laplace for thin-walled spherical shells: Tension $T$ is related to pressure $P$, radius $r$, and tissue thickness $t$ by $T = \\dfrac{P r}{2 t}$.\n    4.  Infectious pathophysiology: Biofilm formation, chronic inflammation, tissue necrosis leading to loss of mechanical integrity.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientifically Grounded:** The problem is firmly grounded in ophthalmology and ophthalmic plastic surgery. The procedures (enucleation, evisceration), implant types (porous polyethylene, PMMA), and complications (exposure, extrusion) are standard clinical entities. The provided principles—wound healing, Laplace's law as a biomechanical model for tissue tension, and infectious pathophysiology—are all scientifically valid and directly applicable to the analysis of these surgical outcomes. The model $T = \\dfrac{P r}{2 t}$ is a valid and commonly used physical approximation for stress in thin membranes under pressure, which is an appropriate analogy for the forces on the soft tissue closure over an orbital implant.\n2.  **Well-Posed:** The problem statement is self-contained. The two clinical vignettes serve as concrete examples of the phenomena to be distinguished. The \"fundamental bases\" provide the necessary theoretical framework. The question is clear and calls for an analysis of the provided options against this framework, allowing for a unique set of correct answers to be determined.\n3.  **Objective:** The language is clinical, precise, and objective, devoid of subjective or ambiguous terminology.\n4.  **Flaw Checklist:**\n    *   No scientific unsoundness is present.\n    *   The problem is formalizable and relevant to the topic.\n    *   The setup is complete and consistent.\n    *   The scenarios and data (e.g., implant size $22$ $\\mathrm{mm}$) are realistic.\n    *   The structure is sound and allows for a definite solution.\n    *   The problem is not trivial; it requires the synthesis of multiple concepts.\n    *   All propositions are scientifically verifiable.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. The solution will now proceed.\n\n### Solution Derivation and Option Analysis\n\nThe core task is to differentiate implant exposure from extrusion, both conceptually and etiologically, using the provided clinical cases and fundamental principles.\n\n*   **Exposure** is a failure of the overlying soft tissue (conjunctiva and Tenon's capsule). The implant remains in its correct position within the orbit but becomes visible due to a defect in its coverage. This is exemplified by Case 1, where there is a \"conjunctival breakdown\" but the \"implant is stable.\" This is a problem of wound healing, often driven by excessive tension, poor vascularity, or localized infection.\n*   **Extrusion** is a failure of the implant's fixation and containment within the orbit. The implant migrates from its intended position and is displaced from the socket. This is exemplified by Case 2, where the implant is \"displaced outside the socket.\" This is a problem of mechanical stability, often driven by infection, formation of a contracting capsule, or lack of tissue integration.\n\nThe provided principles explain the mechanisms:\n*   The **Law of Laplace** ($T = \\dfrac{P r}{2 t}$) explains how biomechanical tension can cause exposure. A large implant (high $r$) or thin/weak tissue closure (low $t$) increases tension on the suture line, potentially causing ischemia and wound breakdown.\n*   **Wound healing principles** highlight the need for adequate blood supply. Compromised vascularity prevents robust tissue coverage, predisposing to exposure.\n*   **Infection and implant material** are critical. Porous implants (polyethylene) allow fibrovascular ingrowth, anchoring the implant and making extrusion less likely. Non-porous implants (PMMA) do not integrate; they become encapsulated. Infection of a non-porous implant can lead to abscess formation and tissue necrosis, destroying the capsule and pushing the unanchored implant out (extrusion).\n\n**Evaluation of Options**\n\n**A. Implant exposure is characterized by loss or thinning of conjunctiva and Tenon capsule with the implant remaining seated within the socket; extrusion denotes displacement of the implant out of the socket such that it is no longer contained by the capsular and soft-tissue envelope, often protruding externally.**\nThis statement provides the precise, standard clinical definitions for exposure and extrusion. Case 1 (\"conjunctival breakdown reveals the underlying...implant surface; the implant is stable\") is a perfect description of exposure. Case 2 (\"implant displaced outside the socket\") is a perfect description of extrusion. This aligns exactly with the first fundamental basis provided.\n**Verdict: Correct.**\n\n**B. For a given intraorbital pressure $P$, increasing implant radius $r$ while maintaining thin anterior coverage thickness $t$ raises anterior lamellar tension $T$ at suture lines per $T = \\dfrac{P r}{2 t}$, biomechanically predisposing to anterior exposure in the early postoperative period.**\nThis is a direct and accurate application of the provided Law of Laplace. An increase in the implant radius $r$ leads to a proportional increase in the wall tension $T$ on the overlying tissues. Excessive tension on a healing surgical wound is a classic cause of wound dehiscence and tissue necrosis due to compromised blood flow. This breakdown of the anterior tissue layers is, by definition, implant exposure. The first patient received a large $22$ $\\mathrm{mm}$ implant, which is a known risk factor for this mechanism of failure.\n**Verdict: Correct.**\n\n**C. Infectious colonization with biofilm is more strongly associated with early exposure than with late extrusion, independent of coverage thickness, because biofilms reduce friction at the implant–tissue interface and thereby protect closure lines from shear.**\nThis statement is fundamentally flawed. Firstly, biofilms are a potent stimulus for chronic inflammation and tissue destruction; they do not \"protect\" tissue. The claim that they reduce friction in a beneficial way is an incorrect application of physics and ignores the destructive biological consequences. Biofilms serve as a nidus for infection, leading to tissue necrosis and breakdown of the closure line, thereby *causing* exposure or extrusion rather than preventing it. Secondly, infection is a major cause of both exposure and extrusion, and its timeline is variable; it can certainly cause late extrusion, as suggested by Case 2 where infection at $2$ weeks culminates in extrusion by $6$ weeks. The reasoning provided is scientifically unsound.\n**Verdict: Incorrect.**\n\n**D. In evisceration with a thin scleral shell, placement of an oversized non-porous PMMA implant increases the risk of extrusion, particularly in the setting of infection, because the lack of fibrovascular ingrowth and inflammatory necrosis undermine device seating and capsular containment.**\nThis statement correctly synthesizes multiple risk factors. An oversized implant increases tension (per Laplace's law). A non-porous PMMA implant does not allow for fibrovascular ingrowth, meaning it never integrates with host tissue and relies solely on a fibrous capsule for stability. Infection leads to inflammatory necrosis, which destroys this weak containing capsule. The combination of an unanchored implant and a compromised capsule in the presence of an inflammatory/infectious process (which can generate pressure via fluid/pus) creates ideal conditions for the implant to be pushed out of the socket, i.e., extrusion. This perfectly explains the pathophysiology of the outcome seen in Case 2.\n**Verdict: Correct.**\n\n**E. Pegging of a hydroxyapatite implant (a porous calcium phosphate implant) reduces exposure risk by mechanically isolating the anterior lamellae from implant motion, thereby lowering shear forces at the conjunctival surface.**\nThis statement is contrary to established clinical facts. Pegging is a procedure to improve the motility of the overlying artificial eye by creating a physical coupling to the orbital implant. This procedure involves drilling through the conjunctiva and Tenon's capsule to access the integrated implant. This disruption of the anterior tissue barrier creates a persistent fistula and is a well-known, significant risk factor *for* implant exposure, discharge, and infection at the peg site. It does not reduce the risk of exposure; it creates a new and significant one.\n**Verdict: Incorrect.**\n\n**F. Postoperative radiotherapy to the orbit generally improves tissue vascularity and wound-healing strength, thereby reducing the likelihood of exposure at anterior closure lines.**\nThis statement is the opposite of the known biological effects of ionizing radiation on tissues. Radiotherapy causes long-term damage to small blood vessels (obliterative endarteritis), leading to chronic ischemia, reduced tissue perfusion, and fibrosis. This severely compromises the healing capacity of tissues. Irradiated tissue is well known to have a much higher rate of wound healing complications, including dehiscence and necrosis. Therefore, prior or postoperative radiotherapy is a major risk factor that *increases* the likelihood of implant exposure.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{ABD}$$", "id": "4673948"}, {"introduction": "The decision to remove an eye versus attempting salvage is one of the most difficult in ophthalmology, requiring a rigorous weighing of outcomes under uncertainty. This advanced exercise introduces formal decision analysis using Bayes’ theorem and patient-centered utilities, such as Quality-Adjusted Life Years ($QALYs$), as a quantitative framework. By deriving a decision threshold, you will learn to synthesize diagnostic data and patient values to guide high-stakes clinical judgment. [@problem_id:4674021]", "problem": "A $68$-year-old patient presents with fulminant endophthalmitis after a contaminated open-globe injury. You must decide between immediate eye removal (enucleation or evisceration) versus aggressive salvage with pars plana vitrectomy and intravitreal antimicrobials. Model the clinical state as a binary latent variable: irredeemable infection $I$ (salvage is biologically futile and increases life-threatening risk) versus salvageable infection $S$. Let the pretest (prior) probability of $I$ be $p_{0} = 0.25$ based on epidemiology and clinical severity. A diagnostic signal $T$ (composite of B-scan ultrasound internal echoes consistent with panophthalmitis and contrast-enhanced Computed Tomography (CT) showing scleral necrosis) has sensitivity $\\operatorname{Se} = 0.90$ and specificity $\\operatorname{Sp} = 0.80$ for $I$. In this patient, $T$ is positive.\n\nOutcomes are quantified in Quality-Adjusted Life Years (QALYs), defined as the time integral of health-related quality of life over the remaining lifespan, normalized so that perfect health for one year equals one QALY. Assume the following patient-specific expected utilities:\n- Salvage if $S$: $U_{SS} = 13.5$ QALYs.\n- Salvage if $I$: $U_{SI} = 4.2$ QALYs.\n- Removal if $S$: $U_{RS} = 12.0$ QALYs.\n- Removal if $I$: $U_{RI} = 11.5$ QALYs.\n\nStarting from the definitions of expected utility and Bayes’ theorem for binary hypotheses, first derive the posterior probability $P(I \\mid T^{+})$ in terms of $p_{0}$, $\\operatorname{Se}$, and $\\operatorname{Sp}$. Next, derive the posterior-probability indifference threshold $p^{\\ast}$ at which the expected utility of removal equals that of salvage, expressed only in terms of $U_{SS}$, $U_{SI}$, $U_{RS}$, and $U_{RI}$. Finally, evaluate $p^{\\ast}$ numerically using the provided utilities. Round your $p^{\\ast}$ to four significant figures and express your final answer as a decimal (unitless). Do not include any units in your final reported value.", "solution": "This problem is a classic application of Bayesian decision theory to a clinical scenario. We are tasked with determining a decision threshold for choosing between two treatments (Salvage vs. Removal) for a patient with endophthalmitis. The decision depends on the unknown true state of the eye, which can be either salvageable ($S$) or irredeemable ($I$). We are given prior probabilities, test characteristics (sensitivity and specificity), and patient-specific utilities in the form of Quality-Adjusted Life Years (QALYs).\n\nFirst, as requested, we derive the general formula for the posterior probability of an irredeemable infection, $P(I \\mid T^{+})$, given a positive test result ($T^{+}$). We use Bayes' theorem for binary hypotheses. The states are $I$ and $S$. The test result is $T^{+}$.\n\nBayes' theorem states:\n$$P(I \\mid T^{+}) = \\frac{P(T^{+} \\mid I) P(I)}{P(T^{+})}$$\n\nThe denominator, $P(T^{+})$, can be expanded using the law of total probability:\n$$P(T^{+}) = P(T^{+} \\mid I) P(I) + P(T^{+} \\mid S) P(S)$$\n\nWe are given the following terms:\n- The prior probability of state $I$: $P(I) = p_{0}$.\n- The prior probability of state $S$: $P(S) = 1 - P(I) = 1 - p_{0}$.\n- The sensitivity of the test for state $I$: $\\operatorname{Se} = P(T^{+} \\mid I)$.\n- The specificity of the test for state $I$: $\\operatorname{Sp} = P(T^{-} \\mid S)$.\n\nThe probability of a positive test given state $S$ is related to the specificity. Since the test outcome is binary (either $T^{+}$ or $T^{-}$), we have:\n$$P(T^{+} \\mid S) = 1 - P(T^{-} \\mid S) = 1 - \\operatorname{Sp}$$\n\nSubstituting these expressions into the formula for $P(T^{+})$ gives:\n$$P(T^{+}) = (\\operatorname{Se})(p_{0}) + (1 - \\operatorname{Sp})(1 - p_{0})$$\n\nFinally, substituting this back into Bayes' theorem yields the desired expression for the posterior probability:\n$$P(I \\mid T^{+}) = \\frac{\\operatorname{Se} \\cdot p_{0}}{\\operatorname{Se} \\cdot p_{0} + (1 - \\operatorname{Sp})(1 - p_{0})}$$\n\nNext, we derive the posterior-probability indifference threshold, $p^{\\ast}$. This is the posterior probability of state $I$ at which the expected utility of the 'Salvage' action is equal to the expected utility of the 'Removal' action. Let $p'$ represent the posterior probability of an irredeemable infection, i.e., $p' = P(I \\mid \\text{data})$. Consequently, the posterior probability of a salvageable infection is $P(S \\mid \\text{data}) = 1 - p'$.\n\nThe expected utility of the 'Salvage' action, $EU(\\text{Salvage})$, is calculated by weighting the utility of each outcome by its posterior probability:\n$$EU(\\text{Salvage}) = U_{SI} \\cdot p' + U_{SS} \\cdot (1 - p')$$\n\nSimilarly, the expected utility of the 'Removal' action, $EU(\\text{Removal})$, is:\n$$EU(\\text{Removal}) = U_{RI} \\cdot p' + U_{RS} \\cdot (1 - p')$$\n\nThe indifference threshold, $p^{\\ast}$, is the value of $p'$ for which $EU(\\text{Salvage}) = EU(\\text{Removal})$. We set the two expressions equal and solve for $p^{\\ast}$:\n$$U_{SI} p^{\\ast} + U_{SS} (1 - p^{\\ast}) = U_{RI} p^{\\ast} + U_{RS} (1 - p^{\\ast})$$\n$$U_{SI} p^{\\ast} + U_{SS} - U_{SS} p^{\\ast} = U_{RI} p^{\\ast} + U_{RS} - U_{RS} p^{\\ast}$$\n\nTo solve for $p^{\\ast}$, we group all terms containing $p^{\\ast}$ on one side of the equation:\n$$U_{SS} - U_{RS} = U_{RI} p^{\\ast} - U_{RS} p^{\\ast} - U_{SI} p^{\\ast} + U_{SS} p^{\\ast}$$\n$$U_{SS} - U_{RS} = p^{\\ast} (U_{RI} - U_{RS} - U_{SI} + U_{SS})$$\nRearranging the terms in the parenthesis gives a more intuitive form:\n$$U_{SS} - U_{RS} = p^{\\ast} \\left( (U_{SS} - U_{RS}) + (U_{RI} - U_{SI}) \\right)$$\n\nSolving for $p^{\\ast}$ yields the indifference threshold expressed in terms of the utilities:\n$$p^{\\ast} = \\frac{U_{SS} - U_{RS}}{(U_{SS} - U_{RS}) + (U_{RI} - U_{SI})}$$\nThis expression represents the ratio of the net benefit of choosing the correct action for state $S$ (Salvage vs. Removal) to the sum of the net benefits of choosing the correct action for each state.\n\nFinally, we evaluate $p^{\\ast}$ numerically using the provided QALY utility values:\n- $U_{SS} = 13.5$\n- $U_{SI} = 4.2$\n- $U_{RS} = 12.0$\n- $U_{RI} = 11.5$\n\nSubstituting these values into the derived formula:\n$$p^{\\ast} = \\frac{13.5 - 12.0}{(13.5 - 12.0) + (11.5 - 4.2)}$$\n$$p^{\\ast} = \\frac{1.5}{1.5 + 7.3}$$\n$$p^{\\ast} = \\frac{1.5}{8.8}$$\n\nCalculating the decimal value:\n$$p^{\\ast} = 0.17045454...$$\n\nRounding to four significant figures as required by the problem statement, we obtain:\n$$p^{\\ast} \\approx 0.1705$$\nThis threshold $p^{\\ast}$ represents the posterior probability of irredeemable infection above which the expected utility of eye removal exceeds that of attempted salvage.", "answer": "$$\\boxed{0.1705}$$", "id": "4674021"}]}